In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.

"Disclosures Drs St-Onge, Héroux, and Bouvier report receiving a provincial grant supporting public-private partnerships from the Fonds de Partenariat pour un Québec innovant et en santé (FPQIS) and research funding as well as in-kind support from Bristol Myers Squibb in the context of the FPQIS grant. Dr Bouvier is also president of the Scientific Advisory Board of Domain Therapeutics (Graffenstaden, France), to which the bioluminescence resonance energy transfer–based biosensors used in the present study have been licensed for commercialization; he does not hold shares in Domain Therapeutics. Dr Gargalovic, Dr Wong, Dr Onorato, Dr Finlay, T. Wang, M. Yan, E. Crain, C. Xu, Dr Chen, Dr Generaux, Dr Lawrence, Dr Wexler, and Dr Gordon were employees of Bristol Myers Squibb (Princeton, NJ) at the time the studies were conducted. Dr Wong also reports holding shares in Bristol Myers Squibb."

"Sources of Funding This work was funded by Bristol Myers Squibb (Princeton, NJ)."